Novartis’ former IP chief urges innovative pharma to emulate high-tech patent strategies
The former global head of pharma intellectual property at Novartis has told IAM that life sciences companies should consider a more tech-like approach to IP management, involving licensing out development patents to competitors, rather than seeking…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.